









市場行情
/
股票
/
nasdaq-nktr
/

Nektar Therapeutics

NKTR

43.940USD

-0.520-1.17%

收盤 12/24, 13:00（美東）報價延遲15分鐘

863.53M總市值

虧損本益比TTM



Nektar Therapeutics

43.940

-0.520-1.17%

概覽公司財務分析

概覽

公司

財務

分析

關於 Nektar Therapeutics 公司

Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Nektar Therapeutics簡介



公司代碼NKTR

公司名稱Nektar Therapeutics

上市日期May 03, 1994

CEORobin (Howard W)

員工數量61

證券類型Ordinary Share

年結日May 03

公司地址455 Mission Bay Boulevard South

城市SAN FRANCISCO

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94158

電話18554826587

網址https://www.nektar.com/

公司代碼NKTR

上市日期May 03, 1994

CEORobin (Howard W)

Nektar Therapeutics公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Howard W. Robin

President, Chief Executive Officer, Director

46.73K

+11.72%

Dr. Jonathan Zalevsky, Ph.D.

Senior Vice President, Chief Research and Development Officer

16.66K

+9.96%

Mr. Jeffrey Robert (Jeff) Ajer

Independent Director

2.28K

Dr. Diana M. Brainard, M.D.

Independent Director

Mr. R. Scott Greer

Independent Director

Mr. Robert B. (Rob) Chess

Independent Chairman of the Board

Ms. Sandra A. Gardiner

Interim Chief Financial Officer

Mr. Mark A. Wilson, J.D.

Senior Vice President, Chief Legal Officer

Mr. Corey Davis

Managing Director

Mr. Roy A. Whitfield

Lead Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Howard W. Robin

President, Chief Executive Officer, Director

46.73K

+11.72%

Dr. Jonathan Zalevsky, Ph.D.

Senior Vice President, Chief Research and Development Officer

16.66K

+9.96%

Mr. Jeffrey Robert (Jeff) Ajer

Independent Director

2.28K

Dr. Diana M. Brainard, M.D.

Independent Director

Mr. R. Scott Greer

Independent Director

Mr. Robert B. (Rob) Chess

Independent Chairman of the Board

收入明細

單位: USD更新時間: 10月6日週一

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

Rest of world

97.05M

98.60%

United States

1.38M

1.40%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月18日週二

持股股東

股東類型

持股股東

佔比

BVF Partners L.P.

6.28%

The Vanguard Group, Inc.

4.66%

Susquehanna International Group, LLP

4.55%

Morgan Stanley & Co. LLC

4.34%

Farallon Capital Management, L.L.C.

3.89%

其他

76.28%

持股股東

佔比

BVF Partners L.P.

6.28%

The Vanguard Group, Inc.

4.66%

Susquehanna International Group, LLP

4.55%

Morgan Stanley & Co. LLC

4.34%

Farallon Capital Management, L.L.C.

3.89%

其他

76.28%

股東類型

持股股東

佔比

Hedge Fund

31.87%

Investment Advisor

21.99%

Investment Advisor/Hedge Fund

8.86%

Research Firm

7.04%

Pension Fund

0.76%

Individual Investor

0.70%

Venture Capital

0.69%

Bank and Trust

0.02%

其他

28.08%

機構持股



更新時間: 10月5日週日

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

342

9.79M

51.46%

-2.29M

2025Q2

342

8.92M

53.56%

-2.95M

2025Q1

408

8.48M

68.15%

-4.47M

2024Q4

427

136.20M

73.84%

-69.28M

2024Q3

442

143.71M

78.07%

-57.20M

2024Q2

458

138.43M

75.38%

-54.08M

2024Q1

477

115.32M

62.79%

-91.21M

2023Q4

499

122.94M

64.45%

-94.24M

2023Q3

522

148.15M

77.94%

-68.45M

2023Q2

531

142.56M

75.34%

-88.27M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

BVF Partners L.P.

1.28M

6.71%

+1.28M

Jul 01, 2025

The Vanguard Group, Inc.

729.49K

3.84%

-91.15K

-11.11%

Jun 30, 2025

Susquehanna International Group, LLP

221.89K

1.17%

+184.74K

+497.33%

Jun 30, 2025

Emerald Advisers LLC

143.29K

0.75%

+389.00

+0.27%

Sep 30, 2025

Millennium Management LLC

649.03K

3.41%

+496.45K

+325.35%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

297.81K

1.57%

-576.08K

-65.92%

Jun 30, 2025

Nantahala Capital Management, LLC

709.76K

3.73%

+190.49K

+36.68%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Invesco Dorsey Wright Healthcare Momentum ETF

4.55%

Simplify Health Care ETF

3.22%

Simplify Propel Opportunities ETF

2.69%

State Street SPDR S&P Pharmaceuticals ETF

1.72%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.48%

Invesco NASDAQ Future Gen 200 ETF

1.17%

Invesco Dorsey Wright SmallCap Momentum ETF

0.95%

iShares U.S. Pharmaceuticals ETF

0.46%

Invesco RAFI US 1500 Small-Mid ETF

0.13%

Schwab U.S. Small-Cap ETF

0.03%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比4.55%

Simplify Health Care ETF

佔比3.22%

Simplify Propel Opportunities ETF

佔比2.69%

State Street SPDR S&P Pharmaceuticals ETF

佔比1.72%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.48%

Invesco NASDAQ Future Gen 200 ETF

佔比1.17%

Invesco Dorsey Wright SmallCap Momentum ETF

佔比0.95%

iShares U.S. Pharmaceuticals ETF

佔比0.46%

Invesco RAFI US 1500 Small-Mid ETF

佔比0.13%

Schwab U.S. Small-Cap ETF

佔比0.03%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Jun 04, 2025

Merger

15→1

公告日期

類型

比率

Jun 04, 2025

Merger

15→1

常見問題

Nektar Therapeutics的前五大股東是誰？



Nektar Therapeutics的前五大股東如下：
BVF Partners L.P.
持有股份：1.28M
佔總股份比例：6.71%。
The Vanguard Group, Inc.
持有股份：729.49K
佔總股份比例：3.84%。
Susquehanna International Group, LLP
持有股份：221.89K
佔總股份比例：1.17%。
Emerald Advisers LLC
持有股份：143.29K
佔總股份比例：0.75%。
Millennium Management LLC
持有股份：649.03K
佔總股份比例：3.41%。